Increased number of shares and votes in Karolinska Development

STOCKHOLM - April 29, 2011. The number of shares and the number of votes in Karolinska Development have changed as a result of a new issue of 15,200,000 series B shares in total, in connection with Karolinska Development's listing on NASDAQ OMX Stockholm. Today, the last trading day of the month, there are in total 48,531,417 shares, divided into 1,503,098 series A shares and 47,028,319 series B shares, and 62,059,299 votes in Karolinska Development. The above information has been made public in accordance with the Financial Instruments Trading Act. The information was submitted for publication at 08.00 am (CET) on April 29, 2011. For further information, please contact: Torbjørn Bjerke, CEO Phone: +46 727-44 41 23, e-mail: Benjamin Nordin, IR Director Phone +46 730-93 60 80, e-mail: TO THE EDITORS About Karolinska Development Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class research into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP these to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out licensing of products. This will result in upfront payments, milestone payments and royalties. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Karolinska Development's flexible exit strategy enables projects to be exited at whichever stage of development offers the greatest return on investment, usually after Phase II clinical trials have indicated the desired pharmaceutical effect on patients - this being an important value enhancing step. Today, the portfolio consists of over 40 projects at various stages, from concept development to Phase II clinical trials, twelve projects are in clinical trials with six in Phase II. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women's health and diseases that affect the central nervous system. Read Press Release as PDF: This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Karolinska Development AB (publ) via Thomson Reuters ONE [HUG#1510325]